Evidence map›Paper›PMID 38927642›Full record

ArticleGenes2024

A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy.

Seren Sevim-Wunderlich, Tu Dang, Jana Rossius, Frank Schnütgen, Ralf Kühn

Abstract read
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How I Treat: Chronic granulomatous disease.Journal of human immunity · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seren Sevim-WunderlichMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.ORCID 0009-0008-2771-4149
Tu DangMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
Jana RossiusMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
Frank SchnütgenDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-2426-6685
Ralf KühnMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.ORCID 0000-0003-1694-9803

Funding

Deutsche Forschungsgemeinschaft KU3389/1-1 , SCHN1166/4-1
6 · The paper itself

Abstract

Chronic granulomatous disease (CGD) is an inherited immunodeficiency disease mainly caused by mutations in the X-linked

Indexed as

CRISPR-Cas SystemsDisease Models, AnimalGenetic TherapyGranulomatous Disease, ChronicNADPH Oxidase 2AnimalsHematopoietic Stem CellsHumansMacrophagesMiceMutationReactive Oxygen SpeciesCybb protein, mouseNADPH Oxidase 2Reactive Oxygen SpeciesCRISPR/Cas9gene therapymouse disease modelX-CGD

Identifiers

PMID38927642
PMCPMC11203339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.